Medartis : Presentation half-year results 2022

2022 | Half-year Results

Presentation for journalists, analysts and investors Basel, 16 August 2022

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions. Further, neither the company nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein or of the views given or implied, and accordingly no reliance should be placed on it.

This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs, expectations and projections about future events, e.g. statements including terms like "potential", "believe", "assume", "expect", "fore-cast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Medartis Holding AG and investments and those explicitly or implicitly presumed in these statements. There are several factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of Medartis Holding AG cannot be relied on as a guide to future performance. Forward-looking statements speak only as of the date of this presentation and Medartis Holding AG, its directors, officers, employees, agents, counsel and advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to, any forward-looking statements in this presentation. No statement in this document or any related materials or given at this presentation is intended as a profit forecast or a profit estimate and no statement in this document or any related materials or given at this presentation should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements.

Unless stated otherwise the information provided in this presentation are based on company in-formation. This presentation is intended to provide a general overview of Medartis Holding AG's business and does not purport to deal with all aspects and details regarding Medartis Holding AG. Accordingly, neither Medartis Holding AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained in the presentation or of the views given or implied. Neither Medartis Holding AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith.

The material contained in this presentation reflects current legislation and the business and financial affairs of Medartis Holding AG which are subject to change and audit.

® Medartis All rights reserved │ 2

AgendaAgenda

Half-year highlights

Christoph Brönnimann, CEO

Financial & business review

Dirk Kirsten, CFO

Update on our 2022 prioritiesChristoph Brönnimann, CEO

Outlook 2022

Christoph Brönnimann, CEO

Q & A

® Medartis All rights reserved ∣ 3

Half-year highlights

Christoph Brönnimann, CEO

Key facts & figures

TOTAL SALES

CHF 88.4 million1

• Strengthening our competitive position in most markets
• Hospital surgical capacity impacted by staff shortages and postponement of elective operations

UNDERLYING2 EBITDA MARGIN

16.3%

• Gross margin improves 0.6 PP
• NSI leads to dilution of reported operating margin, as communicated in March

REVENUE GROWTH

+20.1% CER1 vs. PY

• +18.0% excl. 3rd party sales from NSI
• EMEA (+21% vs. PY) contributed half of the total growth
• Dynamic LATAM (+47% vs. PY) was the fastest growing territory

HEADCOUNT

832 (+28.2% vs. PY)

• 85 jobs created mainly in growth markets
• 98 colleagues from NSI joined on 1 May

1 CER (constant exchange rates) 2 For a better understanding of the operating performance, this release uses the term "underlying", which excludes the effects ® Medartis All rights reserved │ 5 of the NSI acquisition in May 2022. In addition to running costs, this mainly incl. transaction, integration, and US set-up costs.